| scholarly article | Q13442814 |
| P50 | author | Alexandra Durr | Q60820298 |
| Brandon Durant | Q61827272 | ||
| James P. O'Callaghan | Q64408371 | ||
| Emmanuel Brouillet | Q42839922 | ||
| P2093 | author name string | Hua Yu | |
| Fanny Mochel | |||
| Raphael Schiffmann | |||
| Sandrine Humbert | |||
| Vanessa C. Wheeler | |||
| Xingli Meng | |||
| P2860 | cites work | Detection of early behavioral markers of Huntington's disease in R6/2 mice employing an automated social home cage | Q45293617 |
| Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease. | Q45295463 | ||
| High-dose creatine therapy for Huntington disease: a 2-year clinical and MRS study. | Q45296832 | ||
| Length-dependent gametic CAG repeat instability in the Huntington's disease knock-in mouse | Q45297101 | ||
| Mitochondrial respiration and ATP production are significantly impaired in striatal cells expressing mutant huntingtin | Q45297269 | ||
| HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism | Q45298206 | ||
| Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease. | Q45299986 | ||
| Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. | Q45300532 | ||
| Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. | Q45302702 | ||
| Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration | Q45302924 | ||
| Rapid ATP loss caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mouse brain | Q46053255 | ||
| Brain regional levels of adenosine and adenosine nucleotides in rats killed by high-energy focused microwave irradiation. | Q49141284 | ||
| EFFECT OF ISCHEMIA ON KNOWN SUBSTRATES AND COFACTORS OF THE GLYCOLYTIC PATHWAY IN BRAIN | Q51279822 | ||
| Quantitative studies of enzyme-substrate compartmentation, functional coupling and metabolic channelling in muscle cells. | Q52235772 | ||
| Altered Ca2+ responses in muscles with combined mitochondrial and cytosolic creatine kinase deficiencies | Q73205350 | ||
| Huntingtin interacting proteins are genetic modifiers of neurodegeneration | Q21145230 | ||
| Focused microwave irradiation of the brain preserves in vivo protein phosphorylation: comparison with other methods of sacrifice and analysis of multiple phosphoproteins | Q23914346 | ||
| AMP-activated protein kinase phosphorylation in brain is dependent on method of killing and tissue preparation | Q23918058 | ||
| Creatine synthesis and transport during rat embryogenesis: spatiotemporal expression of AGAT, GAMT and CT1. | Q24811264 | ||
| Measurement of protein using bicinchoninic acid | Q26778491 | ||
| A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. | Q27860836 | ||
| Impaired brain creatine kinase activity in Huntington's disease. | Q30468147 | ||
| The power of automated high-resolution behavior analysis revealed by its application to mouse models of Huntington's and prion diseases | Q30478955 | ||
| Dysregulated brain creatine kinase is associated with hearing impairment in mouse models of Huntington disease | Q30499300 | ||
| Early energy deficit in Huntington disease: identification of a plasma biomarker traceable during disease progression | Q33291754 | ||
| Increased metabolism in the R6/2 mouse model of Huntington's disease. | Q33301810 | ||
| Intergenerational and striatal CAG repeat instability in Huntington's disease knock-in mice involve different DNA repair genes | Q33609937 | ||
| Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases | Q33837238 | ||
| Reduced creatine kinase as a central and peripheral biomarker in Huntington's disease | Q33945688 | ||
| Quantification of age-dependent somatic CAG repeat instability in Hdh CAG knock-in mice reveals different expansion dynamics in striatum and liver | Q34012758 | ||
| A polymorphic DNA marker genetically linked to Huntington's disease | Q34255139 | ||
| Selective defect of in vivo glycolysis in early Huntington's disease striatum | Q35634060 | ||
| 3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease. | Q36318579 | ||
| Energy deficit in Huntington disease: why it matters | Q37834195 | ||
| Neurochemical changes in Huntington R6/2 mouse striatum detected by in vivo 1H NMR spectroscopy | Q40204332 | ||
| Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice | Q40436889 | ||
| Neurochemistry and toxin models in Huntington's disease. | Q40599311 | ||
| Cell loss in the motor and cingulate cortex correlates with symptomatology in Huntington's disease | Q42469950 | ||
| Increases in cortical glutamate concentrations in transgenic amyotrophic lateral sclerosis mice are attenuated by creatine supplementation. | Q43572865 | ||
| An increase in the myocardial PCr/ATP ratio in GLUT4 null mice | Q43937069 | ||
| Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington's disease knock-in mice | Q44316963 | ||
| Creatine supplementation in Huntington's disease: a placebo-controlled pilot trial | Q44616594 | ||
| Measurement of sarcoplasmic reticulum Ca2+ ATPase activity using high-performance liquid chromatography | Q44933316 | ||
| Cerebral creatine kinase deficiency influences metabolite levels and morphology in the mouse brain: a quantitative in vivo 1H and 31P magnetic resonance study | Q45039952 | ||
| Increased glucose metabolism and ATP level in brain tissue of Huntington's disease transgenic mice | Q45290567 | ||
| Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease | Q45290871 | ||
| Paradoxical delay in the onset of disease caused by super-long CAG repeat expansions in R6/2 mice. | Q45292233 | ||
| P6195 | funding scheme | extramural research | Q124503498 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cell biology | Q7141 |
| Huntington's disease | Q190564 | ||
| human behavior | Q3769299 | ||
| muscular system | Q7060553 | ||
| P5008 | on focus list of Wikimedia project | Wikimedia–NIOSH collaboration | Q104416361 |
| P304 | page(s) | 1361-1370 | |
| P577 | publication date | 2012-01-06 | |
| P1433 | published in | Journal of Biological Chemistry | Q867727 |
| P859 | sponsor | NIOSH Health Effects Laboratory Division | Q123344455 |
| P1476 | title | Early alterations of brain cellular energy homeostasis in Huntington disease models | |
| P478 | volume | 287 |
| Q28391627 | A broad phenotypic screen identifies novel phenotypes driven by a single mutant allele in Huntington's disease CAG knock-in mice |
| Q28393673 | A dual role for AMP-activated protein kinase (AMPK) during neonatal hypoxic-ischaemic brain injury in mice |
| Q28389607 | A novel manganese-dependent ATM-p53 signaling pathway is selectively impaired in patient-based neuroprogenitor and murine striatal models of Huntington's disease |
| Q45290293 | A study of molecular changes relating to energy metabolism and cellular stress in people with Huntington's disease: looking for biomarkers |
| Q38019034 | AMP-activated protein kinase: new regulation, new roles? |
| Q38998405 | AMPK in Neurodegenerative Diseases |
| Q45288459 | Abnormal response to cortical activation in early stages of Huntington disease |
| Q48259811 | Amyloid-β oligomers transiently inhibit AMP-activated kinase and cause metabolic defects in hippocampal neurons |
| Q92268464 | Cerebral bioenergetic differences measured by phosphorus-31 magnetic resonance spectroscopy between bipolar disorder and healthy subjects living in two different regions suggesting possible effects of altitude |
| Q41930021 | Co-administration of creatine plus pyruvate prevents the effects of phenylalanine administration to female rats during pregnancy and lactation on enzymes activity of energy metabolism in cerebral cortex and hippocampus of the offspring |
| Q28394163 | Combinatorial assessments of brain tissue metabolomics and histopathology in rodent models of human immunodeficiency virus infection |
| Q28393234 | Compensation in Preclinical Huntington's Disease: Evidence From the Track-On HD Study |
| Q28396387 | Conditioned medium of human adipose-derived mesenchymal stem cells mediates protection in neurons following glutamate excitotoxicity by regulating energy metabolism and GAP-43 expression |
| Q55295842 | Dual Therapy with Liraglutide and Ghrelin Promotes Brain and Peripheral Energy Metabolism in the R6/2 Mouse Model of Huntington's Disease. |
| Q43848665 | Early down-regulation of PKCδ as a pro-survival mechanism in Huntington's disease. |
| Q58700269 | Early postnatal behavioral, cellular, and molecular changes in models of Huntington disease are reversible by HDAC inhibition |
| Q48231391 | Effect of leucine administration to female rats during pregnancy and lactation on oxidative stress and enzymes activities of phosphoryltransfer network in cerebral cortex and hippocampus of the offspring |
| Q38013005 | Energy dysfunction in Huntington's disease: insights from PGC-1α, AMPK, and CKB. |
| Q28389950 | Energy failure: does it contribute to neurodegeneration? |
| Q28389710 | Enhanced neuronal glucose transporter expression reveals metabolic choice in a HD Drosophila model |
| Q48044131 | Expanded neurochemical profile in the early stage of Huntington disease using proton magnetic resonance spectroscopy |
| Q28391911 | Gender differences in the effect of tobacco use on brain phosphocreatine levels in methamphetamine-dependent subjects |
| Q38243002 | Genetic modifiers of Huntington's disease |
| Q28386493 | HdhQ111 Mice Exhibit Tissue Specific Metabolite Profiles that Include Striatal Lipid Accumulation |
| Q28390800 | Homeostatic adaptations in brain energy metabolism in mouse models of Huntington disease |
| Q98471370 | Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities |
| Q38663090 | Huntington's Disease: Pathogenic Mechanisms and Therapeutic Targets. |
| Q29248581 | Huntington’s disease blood and brain show a common gene expression pattern and share an immune signature with Alzheimer’s disease |
| Q38918493 | Imaging and spectroscopic approaches to probe brain energy metabolism dysregulation in neurodegenerative diseases |
| Q28391815 | In vivo neurometabolic profiling in patients with spinocerebellar ataxia types 1, 2, 3, and 7 |
| Q28394803 | Inhibition of mitochondrial protein import by mutant huntingtin |
| Q39014909 | Localized changes to glycogen synthase kinase-3 and collapsin response mediator protein-2 in the Huntington's disease affected brain. |
| Q28394301 | Metabolism in HD: still a relevant mechanism? |
| Q64074984 | Mitochondrial Dysfunction in Huntington's Disease; Interplay Between HSF1, p53 and PGC-1α Transcription Factors |
| Q28387647 | Mitochondrial dysfunction in neurodegenerative diseases |
| Q27004209 | Modeling Huntington's disease with induced pluripotent stem cells |
| Q26853025 | Mouse models of polyglutamine diseases: review and data table. Part I |
| Q28387085 | N-Acetylcysteine improves mitochondrial function and ameliorates behavioral deficits in the R6/1 mouse model of Huntington's disease |
| Q47694590 | Neuroprotective Effect of Creatine and Pyruvate on Enzyme Activities of Phosphoryl Transfer Network and Oxidative Stress Alterations Caused by Leucine Administration in Wistar Rats |
| Q45294879 | Oxidizing effects of exogenous stressors in Huntington's disease knock-in striatal cells--protective effect of cystamine and creatine |
| Q28397230 | Oxygen consumption deficit in Huntington disease mouse brain under metabolic stress |
| Q27001671 | PGC-1α, mitochondrial dysfunction, and Huntington's disease |
| Q27011417 | Possible involvement of self-defense mechanisms in the preferential vulnerability of the striatum in Huntington's disease |
| Q28393157 | Pre-symptomatic activation of antioxidant responses and alterations in glucose and pyruvate metabolism in Niemann-Pick Type C1-deficient murine brain |
| Q28388014 | Regulation of neuronal bioenergy homeostasis by glutamate |
| Q28386202 | Role of oxidative DNA damage in mitochondrial dysfunction and Huntington's disease pathogenesis |
| Q28384036 | Shaping the role of mitochondria in the pathogenesis of Huntington's disease |
| Q48248957 | The human OPA1delTTAG mutation induces premature age-related systemic neurodegeneration in mouse. |
| Q47442924 | Towards an Understanding of Energy Impairment in Huntington's Disease Brain |
| Q39422277 | Triheptanoin for the treatment of brain energy deficit: A 14-year experience |
| Q28388261 | Triheptanoin improves brain energy metabolism in patients with Huntington disease |
Search more.